ClinicalTrials.Veeva

Menu

MRI of the Liver With Eovist

University of Washington logo

University of Washington

Status

Terminated

Conditions

Hepatocellular Carcinoma

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT01215838
DI-2009-1
7160 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to determine if a new magnetic resonance (MR) protocol is better at diagnosing liver lesions.

Full description

Hepatocellular carcinoma (HCC), a form of liver cancer, is the seventh most common cause of cancer mortality in the US. The incidence rate of HCC is increasing along with the incidence of Hepatitis B and C which are known to promote HCC. Patients have a better prognosis (survival outlook) if HCC is found and treated at an early stage. MRI is the best imaging modality for diagnosing HCC.

This study will compare standard MRIs and MRIs performed with a newly developed MR protocol to determine if it is possible to more confidently diagnose HCC.

Enrollment

4 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • known hepatocellular carcinoma
  • undergoing MRI of the liver

Exclusion criteria

  • Contraindication to MRI with IV contrast

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems